SCHEMBL10180602

SCHEMBL10180602

COC(=O)c1cc(Cl)cc(Cl)c1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.56
▸ TSHR P16473 2/20 0.56
▸ TDP1 Q9NUW8 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ COMT P21964 1/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ SERPINH1 P50454 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CTDSP1 Q9GZU7 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ FGFR1 P11362 1/20 0.40
▸ PDGFRA P16234 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1116207 0.84 ABL1 (0.54) ALDH1A1TSHRTDP1SMN1; SMN2COMT
SCHEMBL10181187 0.83 ALDH1A1 (0.51) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL10179512 0.81 ALDH1A1 (0.49) ALDH1A1TSHRTDP1SMN1; SMN2COMT
SCHEMBL18225447 0.80 TDP1 (0.39) ALDH1A1TSHRTDP1SMN1; SMN2COMT
SCHEMBL1952775 0.80 ALDH1A1 (0.64) ALDH1A1TSHRTDP1SMN1; SMN2MEN1
SCHEMBL6590740 0.80 TSHR (0.64) ALDH1A1TSHRKMT2AFLT1KDR
SCHEMBL2211359 0.77 KMT2A (0.50) ALDH1A1TSHRTDP1SMN1; SMN2MEN1
SCHEMBL12000739 0.77 TDP1 (0.49) ALDH1A1TDP1MEN1KMT2AABL1
SCHEMBL2043408 0.77 MEN1 (0.50) TDP1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL2310798 0.76 TDP1 (0.48) ALDH1A1TDP1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474536-B1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF IHARA CHEMICAL IND CO (JP) 2014-06-25 — — EP disclosed
US-20120178931-A1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF IHARA CHEMICAL INDUSTRY CO., LTD (JP) 2012-07-12 — — US disclosed
EP-2474536-A1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF Ihara Chemical Industry Co., Ltd. (JP) 2012-07-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178931-A1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF DPYD, UMPS, PNP ALDH1A1 238/4885TSHR 3409/4885TDP1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback